Corcept Therapeutics CORT -4.84% Get Free Report has outperformed the market over the past 20 years by 7.21% on an annualized ...

Corcept Therapeutics Incorporated’s CORT share price has dipped by 7.02%, which has investors questioning if this is right ...

Corcept Therapeutics (CORT) closed the last trading session at $91.93, gaining 64.2% over the past four weeks, but there could be plenty of upside left in the stock if short-term price targets set by ...

Corcept Therapeutics Incorporated’s CORT share price has surged by 82.59%, which has investors questioning if this is right ...

In this article, we are going to take a look at where Corcept Therapeutics Incorporated (NASDAQ:CORT) stands against other firms that kicked off the trading week stronger. The stock market began the ...

Corcept Therapeutics CORT over the past quarter, offering a diverse set of opinions from bullish to bearish. The table below provides a snapshot of their recent ratings, showcasing how sentiments have ...

Piper Sandler analyst David Amsellem raised the firm’s price target on Corcept Therapeutics (CORT) to $131 from $128 and keeps an Overweight ...

Equities researchers at Zacks Research lifted their Q1 2026 earnings per share (EPS) estimates for shares of Corcept ...

Corcept Therapeutics shares nearly doubled in premarket trading Monday after the company said it received positive data from its phase 3 ovarian cancer treatment trial. Shares rose 93% ahead of the ...

Truist analyst Joon Lee raised the firm’s price target on Corcept Therapeutics (CORT) to $150 from $76 and keeps a Buy rating on the shares.

A new drug tested in a phase 3 trial showed significant improvement in patients with treatment-resistant ovarian cancer.